Risk versus benefit considerations for the β2-agonists

Pharmacotherapy

Volumn 26, Issue 9 II, 2006, Pages

  Kelly, H William ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

2 adrenergic receptor agonists; Albuterol; Asthma; Bronchial spasm; Chronic obstructive pulmonary disease; COPD; Inhaled corticosteroids; Stereoisomerism

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENYLATE CYCLASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLIC AMP; FORMOTEROL; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; LEVALBUTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLACEBO; RANTES; SALBUTAMOL; SALMETEROL;

ASTHMA; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CARDIOVASCULAR EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; HUMAN; INFLAMMATION; PHARMACOGENETICS; QT PROLONGATION; RISK BENEFIT ANALYSIS; SMOOTH MUSCLE RELAXATION; STEREOISOMERISM; TACHYCARDIA; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-AGONISTS; ASTHMA; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; PHARMACOGENETICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; RISK ASSESSMENT;

EID: 33748100753     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.9part2.164S     Document Type: Conference Paper

References (60)

1. Speizer FE, Doll R, Heaf P, Strang LB. Investigation into use of drugs preceding death from asthma. Br Med J 1968;1:339-43.
2. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990;336: 1391-6.
3. Kelly HW, Sorkness CA. Asthma. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 6th ed. New York: McGraw Hill, 2005:503-35.
4. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244-9.
5. Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 2003;90:583-92.
6. 2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37-45.
7. Handley DA. Single-isomer β-agonists. Pharmacotherapy 2001;21(3 pt 2):S21-7.
8. Canning B. Pharmacological properties of (S)-albuterol in human airway smooth muscle preparations [abstr]. Am J Respir Crit Care Med 2002;165:A770.
9. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004;113:503-10.
10. 2-selective sympathomimetics. Pulm Pharmacol 1994;7:367-76.
11. Volcheck GW, Kelkar P, Bartemes KR, et al. Effects of (R)- and (S)-isomers of β-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005;35:1341-6.
12. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160:1136-41.
13. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting β-agonists, a randomised controlled trial [online exclusive article]. Respir Res 2005;6:107. Available from http://respiratory-research.eom/ content/6/1/l07.
14. Haney S, Hancox RJ. Rapid onset of tolerance to β-agonist bronchodilation. Respir Med 2005;99:566-71.
15. 2-agonists. Thorax 2001;56: 529-35.
16. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 1992;327:1420-5.
17. Fitzgerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 study group. J Allergy Clin Immunol 1999;103(3 pt 1):427-35.
18. van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CL. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990;86:793-800.
19. 2-agonists. Respir Med 2002;96:155-62.
20. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004;22:29-36.
21. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest 2002;121;846-51.
22. Au DH, Lemaitre RN, Curtis JR, Smith NL. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Respir Crit Care Med 2000;161:827-30.
23. 2- adrenergic receptor agonists and primary cardiac arrest. Am J Med 2002;113:711-16.
24. Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996;154:1598-602.
25. Suissa S, Assimes T, Ernst P. Inhaled short-acting β-agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003;58:43-6.
26. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000;55:650-6.
27. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma, J Allergy Clin Immunol 1998;102(6 pt 1):943-52.
28. Pleskow WW, Nelson HS, Schaefer K, Claus R, Roach JM. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004;25:429-36.
29. Raissy HH, Esparham A, Harkins M, et al. A double-blind, placebo-controlled crossover comparison of the dose-response to levalbuterol for reversing methacholine-induced bronchoconstriction with and without pretreatment with S-albuterol. Presented at the international conference of the American Thoracic Society, San Diego, May 20-25, 2005.
30. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to β-agonists during acute bronchoconstriction. Eur Respir J 1999;14:283-7.
31. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 2001;17:368-73.
32. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998;11:1-6.
33. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997;52:845-8.
34. 2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999;103: 1049-53.
35. Ramsay CM, Cowan J, Flannery E, McLachlan C, Taylor DR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999;55:353-9.
36. 2-Agonists. In: Murphy S, Kelly HW, eds. Pediatric asthma (lung biology in health and disease series/126). New York: Marcel Dekker, Inc., 1999:1-608.
37. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000;117:156-62.
38. 2-agonist use in patients with asthma. Ann Intern Med 2004;140:802-13.
39. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65-9.
40. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER Jr. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999;107:209-13.
41. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled β-agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48:134-8.
42. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization from asthma. JAMA 1997;277:887-91.
43. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
44. Sin DD, Man J, Sharpe H, Can WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367-76.
45. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, for the SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
46. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
47. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4.
48. Shore SA, Drazen JM. β-Agonists and asthma: too much of a good thing? J Clin Invest 2003;112:495-7.
49. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162:75-80.
50. . 50. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 2004;364:1505-12.
51. 2-adrenoceptor polymorphism. Thorax 2000;55:762-7.
52. Taylor DR, Town GI, Herbison GP, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998;53:744-52.
53. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma clinical research network. N Engl J Med 1996;335:841-7.
54. Wechsler ME, Lehman E, Lazarus SC, et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006;173:519-26.
55. 2- agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-93.
56. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594-603.
57. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001;107:783-9.
58. 58; Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. N Engl J Med 1997;337:1405-11.
59. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET international study group. Am J Respir Crit Care Med 1999;160:594-9.
60. National Heart, Blood, and Lung Institute. National Institutes of Health. Expert panel 2 report: guidelines for the diagnosis and management of asthma. NIH publication no. 97-4051. Bethesda, MD: U.S. Department of Health and Human Services, July 1997.